Effect of renin-angiotensin system inhibitors on cardiovascular events in hemodialysis patients with hyperphosphatemia: A post hoc analysis of the LANDMARK trial

Article Urology & Nephrology

Target phosphate and calcium levels in patients undergoing hemodialysis: a post-hoc analysis of the LANDMARK study

Kiryu Yoshida et al.

Summary: According to a post-hoc analysis, maintaining albumin-adjusted calcium levels below 9.1 mg/dL may reduce the cardiovascular risk in patients undergoing hemodialysis, while hypophosphatemia (<3.6 mg/dL) may be associated with mortality.

CLINICAL AND EXPERIMENTAL NEPHROLOGY (2023)

添加到收藏夹

Article Urology & Nephrology

CKD-Associated Cardiovascular Mortality in the United States: Temporal Trends From 1999 to 2020

Ofer Kobo et al.

Summary: Between 1999 and 2020, there was a slight decrease in cardiovascular-related mortality among patients with chronic kidney disease (CKD) in the United States, while non-cardiovascular-related mortality showed a significant increase. Black patients had consistently higher cardiovascular mortality rates, while Hispanic patients had a greater reduction in cardiovascular mortality.

KIDNEY MEDICINE (2023)

添加到收藏夹

Article Urology & Nephrology

Association of Serum Phosphate with Efficacy of Statin Therapy in Hemodialysis Patients

Ziad A. Massy et al.

Summary: The study revealed that statins have limited treatment efficacy in patients on dialysis with hyperphosphatemia. Higher serum phosphate levels, both at baseline and during treatment, were associated with reduced protective effects of statins on major adverse cardiovascular events and all-cause death. This suggests that the presence of hyperphosphatemia may contribute to the resistance of dialysis patients to statins.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

添加到收藏夹

Review Urology & Nephrology

Cardiac metabolic remodelling in chronic kidney disease

Nikayla Patel et al.

Summary: Chronic kidney disease is associated with an increased risk of cardiovascular disease, such as heart failure. Understanding the metabolic remodeling of the heart in chronic kidney disease can help develop new treatments for cardiac complications.

NATURE REVIEWS NEPHROLOGY (2022)

添加到收藏夹

Article Urology & Nephrology

Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial

Hiroaki Ogata et al.

Summary: The study found that in hemodialysis patients, treatment with lanthanum carbonate (LC) did not delay the progression of vascular calcification compared to treatment with calcium carbonate (CC) for hyperphosphatemia.

CLINICAL AND EXPERIMENTAL NEPHROLOGY (2022)

添加到收藏夹

Review Urology & Nephrology

KDIGO 2022 CLINICAL PRACTICE GUIDELINE FOR DIABETES MANAGEMENT IN CHRONIC KIDNEY DISEASE

Ian H. de Boer et al.

Summary: The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) is a focused update of the 2020 guideline, providing treatment recommendations for clinicians treating diabetes and CKD based on systematic reviews of relevant studies.

KIDNEY INTERNATIONAL (2022)

添加到收藏夹

Review Urology & Nephrology

KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Abstracts

[Anonymous]

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Article Urology & Nephrology

Hyperphosphatemia in chronic kidney disease exacerbates atherosclerosis via a mannosidases-mediated complex-type conversion of SCAP N-glycans

Chao Zhou et al.

Summary: Recent studies suggest that hyperphosphatemia may accelerate atherosclerosis in CKD patients by aberrantly activating the SREBP and SCAP-SREBP2 signaling pathways. High phosphate levels are positively correlated with increased risk of atherosclerotic cardiovascular disease in Chinese CKD patients, and severe atheromatous lesions are observed in the aortas of ApoE knockout mice.

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial

Hiroaki Ogata et al.

Summary: This open-label randomized clinical trial found that adding calcium-based phosphate binders did not significantly reduce cardiovascular events compared with lanthanum carbonate-based treatment alone in patients with hyperphosphatemia undergoing hemodialysis. The study suggests that non-calcium-based phosphate binders may not be more effective than calcium-based binders in reducing cardiovascular events among these patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Peripheral Vascular Disease

Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers A Multinational Cohort Study

RuiJun Chen et al.

Summary: In a large-scale observational study, it was found that ARBs do not significantly differ in effectiveness compared to ACE inhibitors as first-line treatment for hypertension, but present a better safety profile. This supports the preferential prescription of ARBs over ACE inhibitors when initiating treatment for hypertension.

HYPERTENSION (2021)

添加到收藏夹

Review Medicine, General & Internal

Chronic kidney disease

Kamyar Kalantar-Zadeh et al.

Summary: Chronic kidney disease is a progressive disease with no cure, and preserving kidney function through lifestyle adjustments and pharmacological interventions can improve outcomes. A plant-dominant, low-protein, and low-salt diet may help mitigate glomerular hyperfiltration and preserve renal function. Various pharmacotherapies can also be used to alter intrarenal haemodynamics and protect the kidney from further damage.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey

Aminu K. Bello et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

添加到收藏夹

Article Urology & Nephrology

DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients

Angelo Karaboyas et al.

KIDNEY INTERNATIONAL (2018)

添加到收藏夹

Article Urology & Nephrology

Design and baseline characteristics of the LANDMARK study

Hiroaki Ogata et al.

CLINICAL AND EXPERIMENTAL NEPHROLOGY (2017)

添加到收藏夹

Article Hematology

RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan

Masahide Mizobuchi et al.

THERAPEUTIC APHERESIS AND DIALYSIS (2017)

添加到收藏夹

Article Urology & Nephrology

Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials

Youxia Liu et al.

BMC NEPHROLOGY (2017)

添加到收藏夹

Editorial Material Urology & Nephrology

KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Foreword

David C. Wheeler et al.

KIDNEY INTERNATIONAL SUPPLEMENTS (2017)

添加到收藏夹

Article Urology & Nephrology

Estimated GFR Trajectories of People Entering CKD Stage 4 and Subsequent Kidney Disease Outcomes and Mortality

Yan Xie et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2016)

添加到收藏夹

Review Urology & Nephrology

Phosphate-a poison for humans?

Hirotaka Komaba et al.

KIDNEY INTERNATIONAL (2016)

添加到收藏夹

Article Medicine, General & Internal

The heart and vascular system in dialysis

Christoph Wanner et al.

LANCET (2016)

添加到收藏夹

Article Transplantation

Molecular regulation of the renin-angiotensin system in haemodialysis patients

Johannes J. Kovarik et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)

添加到收藏夹

Article Transplantation

Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial

Rajiv Agarwal et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Reninangiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan

Chao-Hsiun Tang et al.

EUROPEAN JOURNAL OF HEART FAILURE (2013)

添加到收藏夹

Article Transplantation

Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial

Kunitoshi Iseki et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2013)

添加到收藏夹

Article Hematology

Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder

Masafumi Fukagawa et al.

THERAPEUTIC APHERESIS AND DIALYSIS (2013)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis

Tara I. Chang et al.

AMERICAN HEART JOURNAL (2011)

添加到收藏夹

Article Medicine, Research & Experimental

FGF23 induces left ventricular hypertrophy

Christian Faul et al.

JOURNAL OF CLINICAL INVESTIGATION (2011)

添加到收藏夹

Review Urology & Nephrology

Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

Charles A. Herzog et al.

KIDNEY INTERNATIONAL (2011)

添加到收藏夹

Article Urology & Nephrology

Cardiovascular Effects of Angiotensin Converting Enzyme Inhibition or Angiotensin Receptor Blockade in Hemodialysis: A Meta-Analysis

Davina J. Tai et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)

添加到收藏夹

Article Urology & Nephrology

Blockage of the Renin-Angiotensin System Attenuates Mortality but Not Vascular Calcification in Uremic Rats: Sevelamer Carbonate Prevents Vascular Calcification

Masanori Tokumoto et al.

AMERICAN JOURNAL OF NEPHROLOGY (2009)

添加到收藏夹

Article Medicine, General & Internal

Cardiovascular and Noncardiovascular Mortality Among Patients Starting Dialysis

Dinanda J. de Jager et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)

添加到收藏夹

Article Urology & Nephrology

Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: An open-label randomized controlled trial

Hiromichi Suzuki et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2008)

添加到收藏夹

Article Transplantation

Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study

Akihiko Takahashi et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)

添加到收藏夹

Article Urology & Nephrology

Effect of ramipril on left ventricular mass in normotensive hemodialysis patients

WC Yu et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2006)

添加到收藏夹

Article Medicine, General & Internal

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol

LH Lindholm et al.

LANCET (2002)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril

J Mathew et al.

CIRCULATION (2001)

添加到收藏夹

Article Medicine, General & Internal

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

EJ Lewis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

添加到收藏夹

Article Medicine, General & Internal

Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.

DV Exner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

添加到收藏夹

Article Medicine, General & Internal

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction:: a systematic overview of data from individual patients

MD Flather et al.

LANCET (2000)

添加到收藏夹

Effect of renin-angiotensin system inhibitors on cardiovascular events in hemodialysis patients with hyperphosphatemia: A post hoc analysis of the LANDMARK trial

相关参考文献

导出引文

分享论文